RT Journal Article
SR Electronic
T1 COVID-19 Vaccine Acceptance and Hesitancy in Low and Middle Income Countries, and Implications for Messaging
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.03.11.21253419
DO 10.1101/2021.03.11.21253419
A1 Solís Arce, Julio S.
A1 Warren, Shana S.
A1 Meriggi, Niccoló F.
A1 Scacco, Alexandra
A1 McMurry, Nina
A1 Voors, Maarten
A1 Syunyaev, Georgiy
A1 Malik, Amyn Abdul
A1 Aboutajdine, Samya
A1 Armand, Alex
A1 Asad, Saher
A1 Augsburg, Britta
A1 Bancalari, Antonella
A1 Nyqvist, Martina Björkman
A1 Borisova, Ekaterina
A1 Bosancianu, Constantin Manuel
A1 Cheema, Ali
A1 Collins, Elliott
A1 Farooqi, Ahsan Zia
A1 Fracchia, Mattia
A1 Guariso, Andrea
A1 Hasanain, Ali
A1 Kamwesigye, Anthony
A1 Kreps, Sarah
A1 Levine, Madison
A1 Littman, Rebecca
A1 Platas, Melina
A1 Ramakrishna, Vasudha
A1 Shapiro, Jacob N.
A1 Svensson, Jakob
A1 Vernot, Corey
A1 Vicente, Pedro C.
A1 Weissinger, Laurin B
A1 Zhang, Baobao
A1 Karlan, Dean
A1 Callen, Michael
A1 Teachout, Matthieu
A1 Humphreys, Macartan
A1 Omer, Saad B.
A1 Mobarak, Ahmed Mushfiq
YR 2021
UL http://medrxiv.org/content/early/2021/05/12/2021.03.11.21253419.abstract
AB We analyze COVID-19 vaccine acceptance across 15 survey samples covering ten low- and middle-income countries (LMICs) in Asia, Africa, and South America, Russia (an upper-middle-income country), and the United States, using survey responses from 44,260 individuals. We find considerably higher willingness to take a COVID-19 vaccine in LMIC samples (80% on average) compared to the United States (65%) and Russia (30%). Vaccine acceptance was primarily explained by an interest in personal protection against COVID-19, while concern about side effects was the most commonly expressed reason for reluctance. Health workers were the most trusted sources of information about COVID-19 vaccines. Our findings suggest that prioritizing vaccine distribution to LMICs should yield high returns in promoting global immunization coverage, and that vaccination campaigns in these countries should focus on translating acceptance into uptake. Messaging highlighting vaccine efficacy and safety, delivered by healthcare workers, may be most effective in addressing remaining hesitancy.Competing Interest StatementThe authors have declared no competing interest.Funding StatementBeyond Conflict, Bill and Melinda Gates Foundation, Columbia University, Givewell.org, Ghent University, HSE University Basic Research Program, International Growth Centre, Jameel Poverty Action Lab Crime and Violence Initiative, London School of Economics and Political Science, Mulago Foundation, NOVAFRICA at the Nova School of Business and Economics, NYU Abu Dhabi, Oxford Policy Management, Social Science Research Council, Trinity College Dublin COVID19 Response Funding, UK Aid, UKRI GCRF/Newton Fund, United Nations Office for Project Services, Weiss Family Fund, WZB Berlin Social Science Center, Yale Institute for Global Health, Yale Macmillan Center, and anonymous donors to IPA and Y-RISE.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This research was approved by multiple IRBs and they are listed in the appendix.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesCode and output of the analysis can be consulted here https://wzb-ipi.github.io/covid_vaccines/replication.html. https://wzb-ipi.github.io/covid_vaccines/replication.html